.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, people along with metastatic gastrointestinal cysts who obtained biomarker-matched therapies based on spreading growth DNA profiling revealed a higher scientific perk than those receiving incomparable therapy.